Brokerages Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $253.69

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $253.69.

Several equities research analysts recently weighed in on BGNE shares. StockNews.com started coverage on BeiGene in a research note on Sunday. They set a “hold” rating for the company. TD Cowen boosted their target price on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley reaffirmed an “overweight” rating and set a $300.00 price target on shares of BeiGene in a research report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd.

Insider Activity

In other news, insider Xiaodong Wang sold 40,468 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the transaction, the director now directly owns 791,493 shares in the company, valued at approximately $148,222,894.11. The trade was a 56.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,119,245 shares of company stock valued at $209,700,084. Company insiders own 7.43% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Blue Trust Inc. increased its holdings in shares of BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares during the period. Truist Financial Corp grew its holdings in BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after acquiring an additional 140 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in BeiGene during the third quarter worth $36,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in BeiGene by 0.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company’s stock worth $21,978,000 after acquiring an additional 266 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in BeiGene during the third quarter worth $67,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Price Performance

The stock’s fifty day simple moving average is $194.32 and its 200 day simple moving average is $188.98. The stock has a market capitalization of $18.03 billion, a PE ratio of -22.42 and a beta of 0.57. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

BeiGene (NASDAQ:BGNE) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 EPS. As a group, sell-side analysts anticipate that BeiGene will post -5.64 EPS for the current year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.